Project Grant R21AI183177
Award Date
11/21/24
Completion Date
10/31/26
Dollars Obligated
$233K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Galveston, TX 77555, USA
Similar Awards
The University of Texas Medical Branch at Galveston received a $463,698 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research) on June 11, 2025. The grant will fund pre-clinical studies to repurpose FDA-approved adenosine A2A receptor antagonists for the treatment of lethal rickettsial infections, which are difficult to diagnose and treat. The research aims to determine the role of A2A receptor signaling in...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $440,000 to the University of Texas Medical Branch at Galveston (UTMB) to conduct research on the role of rickettsial proteins and host microRNAs in exosome formation and pathogenesis of rickettsial diseases. The research aims to determine if the rickettsial cold shock protein A (CspA) can act as an exosome-specific...
This $160,500 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports the development of a library of Rickettsia species isolates from ticks collected in the southern U.S. and Central America. The project aims to (1) build a repository of Rickettsia isolates from over 350 ticks previously collected, and (2) conduct molecular characterization of the isolated Rickettsia species....
This $520,128 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research by the University of Texas Medical Branch at Galveston (UTMB) to investigate how the bacterium Ehrlichia chaffeensis manipulates RNA splicing factors like HNRNPA2B1 to modulate host macrophage defenses and promote infection. The 5-year project aims to understand how the bacterial effector protein TRP120 ubiquitinates and...
This Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $1,649,910 to Tufts University School of Medicine to support research on the human immune response to spotted fever rickettsiosis transmitted by ticks. The 5-year project aims to differentiate the immune responses to three spotted fever group Rickettsia species using a guinea pig model that closely mimics human...
The University of Texas Medical Branch at Galveston received a $440,000 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research) on July 17, 2025. The grant will fund research to characterize the role of tripartite motif (TRIM) proteins in regulating the host innate immune response against vector-borne bunyavirus infections, using Rift Valley fever virus and La Crosse virus as model systems. The goal is to advance...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $3,089,360 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Rutgers, The State University of New Jersey. The 5-year grant, which began on September 10, 2025, will establish a consortium of experienced investigators and a global network of clinical research sites to support the evaluation of early-stage tuberculosis (TB) diagnostic tests. The program aims to accelerate the...
The federal Project Grant award of $850,711 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research at the Albert Einstein College of Medicine to develop novel biomarkers for the detection of tuberculosis (TB). The goal is to identify highly sensitive and specific non-sputum-based point-of-care tests (POCTs) for active TB diagnosis, particularly in resource-limited settings and people living...
This $4,760,584 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to address the critical unmet need for better tuberculosis (TB) diagnostics in high-burden countries. The primary objectives are to: Solicit, review, and prioritize the most relevant novel TB diagnostics across different phases of development and use cases for evaluation during the award period. Conduct...
The Project Grant award of $743,651 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) will fund research to develop plasma cell-free RNA (cfRNA) signatures as a novel biomarker for tuberculosis (TB) diagnosis and treatment monitoring. The Regents of the University of California, San Francisco will lead this 5-year translational research project, which aims to validate the accuracy of cfRNA signatures in detecting active TB...